FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386475138> ?p ?o ?g. }

• W4386475138 abstract "<p>MAPKi resistant cells show decreased ATM expression. <b>A,</b> Immunoblot analysis of A375 R cells treated with 5 μmol/L talazoparib (Tala.) for 24 hours or untreated (Ctr.). Relative protein expression is shown. Actin control was reused from <a href=#fig2 target=_blank>Fig. 2E</a> as the Western blots were performed in the same experiment. <b>B,</b> Immunoblot analysis of chromatin bound fraction of A375 S and R cells after the treatment with 0.005% MMS and 2 μmol/L talazoparib (+) for 6 hours or untreated cells (−). Relative protein expression is shown. <b>C,</b> RT² Profiler PCR Array Human DNA Repair was performed in A375 S versus R<b>.</b> log₂ fold change in the expression of the corresponding genes of R compared with S cells as well as the log₁₀<i>P</i> values of the respective gene expression changes are shown in the volcano plot. Technical triplicates were performed. <b>D,</b> Immunoblot analysis of A375 and Mel1617 S and R cells. Relative protein expression is shown. <b>E,</b> Relative ATM gene expression of A375 and Mel1617 S and R is shown. Unpaired <i>t</i> test was performed to compare the Ctr. with Tala. group. <b>F,</b> IHC of paraffin-embedded tumors of a patient before and after MAPKi resistance stained for ATM. 10X magnification was used. Quantification of the ATM positive cells was performed and % ATM positive cells is shown. <b>G,</b> MUH cell viability assay of HT-144 melanoma cell line treated with different concentrations of talazoparib (Tala.) starting at 50 μmol/L for 72 hours. IC₅₀ level is shown. <b>H,</b> MUH cell viability assay of A375 S and R cells treated with different concentrations of Ku-55933 (Ku.) for 72 hours. Comparison of fits of the nonlinear regression was performed to analyze statistical differences between S and R cells. <b>I,</b> MUH cell viability assay of A375 S cells treated with different concentrations of talazoparib for 72 hours. Cells were additionally treated with a stable concentration of 2 μmol/L Ku-55933 or remained untreated. Comparison of fits of the nonlinear regression was performed to analyze statistical differences between cells treated with Ku-55933 or untreated cells.</p>" @default.
• W4386475138 created "2023-09-07" @default.
• W4386475138 creator A5001321067 @default.
• W4386475138 creator A5004823373 @default.
• W4386475138 creator A5017218622 @default.
• W4386475138 creator A5035374008 @default.
• W4386475138 creator A5075470070 @default.
• W4386475138 creator A5080628640 @default.
• W4386475138 creator A5083713436 @default.
• W4386475138 creator A5092618170 @default.
• W4386475138 date "2023-09-06" @default.
• W4386475138 modified "2023-09-27" @default.
• W4386475138 title "FIGURE 3 from PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>" @default.
• W4386475138 doi "https://doi.org/10.1158/2767-9764.24089900" @default.
• W4386475138 hasPublicationYear "2023" @default.
• W4386475138 type Work @default.
• W4386475138 citedByCount "0" @default.
• W4386475138 crossrefType "posted-content" @default.
• W4386475138 hasAuthorship W4386475138A5001321067 @default.
• W4386475138 hasAuthorship W4386475138A5004823373 @default.
• W4386475138 hasAuthorship W4386475138A5017218622 @default.
• W4386475138 hasAuthorship W4386475138A5035374008 @default.
• W4386475138 hasAuthorship W4386475138A5075470070 @default.
• W4386475138 hasAuthorship W4386475138A5080628640 @default.
• W4386475138 hasAuthorship W4386475138A5083713436 @default.
• W4386475138 hasAuthorship W4386475138A5092618170 @default.
• W4386475138 hasBestOaLocation W43864751381 @default.
• W4386475138 hasConcept C104317684 @default.
• W4386475138 hasConcept C11960822 @default.
• W4386475138 hasConcept C150194340 @default.
• W4386475138 hasConcept C153911025 @default.
• W4386475138 hasConcept C185592680 @default.
• W4386475138 hasConcept C55493867 @default.
• W4386475138 hasConcept C57074206 @default.
• W4386475138 hasConcept C86803240 @default.
• W4386475138 hasConceptScore W4386475138C104317684 @default.
• W4386475138 hasConceptScore W4386475138C11960822 @default.
• W4386475138 hasConceptScore W4386475138C150194340 @default.
• W4386475138 hasConceptScore W4386475138C153911025 @default.
• W4386475138 hasConceptScore W4386475138C185592680 @default.
• W4386475138 hasConceptScore W4386475138C55493867 @default.
• W4386475138 hasConceptScore W4386475138C57074206 @default.
• W4386475138 hasConceptScore W4386475138C86803240 @default.
• W4386475138 hasLocation W43864751381 @default.
• W4386475138 hasOpenAccess W4386475138 @default.
• W4386475138 hasPrimaryLocation W43864751381 @default.
• W4386475138 hasRelatedWork W2009966535 @default.
• W4386475138 hasRelatedWork W2019988726 @default.
• W4386475138 hasRelatedWork W2021297725 @default.
• W4386475138 hasRelatedWork W2082530227 @default.
• W4386475138 hasRelatedWork W2088063203 @default.
• W4386475138 hasRelatedWork W2171277769 @default.
• W4386475138 hasRelatedWork W2353446510 @default.
• W4386475138 hasRelatedWork W2385534162 @default.
• W4386475138 hasRelatedWork W2803323662 @default.
• W4386475138 hasRelatedWork W4214823340 @default.
• W4386475138 isParatext "false" @default.
• W4386475138 isRetracted "false" @default.
• W4386475138 workType "article" @default.